AstraZeneca PLC AZN
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 62.38B | 61.37B | 60.44B | 58.74B | 58.13B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 62.38B | 61.37B | 60.44B | 58.74B | 58.13B |
| Cost of Revenue | 11.30B | 11.18B | 11.12B | 10.69B | 9.67B |
| Gross Profit | 51.08B | 50.19B | 49.32B | 48.05B | 48.46B |
| SG&A Expenses | 21.18B | 21.30B | 20.59B | 20.19B | 19.34B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -530.00M | -343.00M | -270.00M | -162.00M | -253.00M |
| Total Operating Expenses | 46.36B | 46.56B | 45.73B | 44.69B | 42.47B |
| Operating Income | 16.02B | 14.81B | 14.71B | 14.05B | 15.66B |
| Income Before Tax | 13.30B | 12.59B | 12.91B | 12.40B | 11.44B |
| Income Tax Expenses | 2.27B | 2.13B | 2.52B | 2.17B | 2.04B |
| Earnings from Continuing Operations | 11.03K | 10.45K | 10.39K | 10.23K | 9.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -4.00M | -7.00M | -4.00M | -8.00M | -5.00M |
| Net Income | 11.03B | 10.45B | 10.39B | 10.23B | 9.40B |
| EBIT | 16.02B | 14.81B | 14.71B | 14.05B | 15.66B |
| EBITDA | 21.20B | 20.08B | 19.78B | 19.03B | 20.17B |
| EPS Basic | 7.11 | 6.74 | 6.70 | 6.59 | 6.06 |
| Normalized Basic EPS | 5.88 | 5.43 | 5.38 | 5.14 | 5.78 |
| EPS Diluted | 7.06 | 6.68 | 6.64 | 6.54 | 6.02 |
| Normalized Diluted EPS | 5.84 | 5.39 | 5.35 | 5.10 | 5.74 |
| Average Basic Shares Outstanding | 6.20B | 6.20B | 6.20B | 6.20B | 6.20B |
| Average Diluted Shares Outstanding | 6.24B | 6.25B | 6.24B | 6.24B | 6.24B |
| Dividend Per Share | 3.23 | 3.23 | 3.20 | 3.20 | 3.13 |
| Payout Ratio | 44.92% | 46.90% | 47.24% | 48.59% | 52.89% |